Home > Journals > Minerva Biotechnology and Biomolecular Research > Past Issues > Minerva Biotechnology and Biomolecular Research 2022 December;34(4) > Minerva Biotechnology and Biomolecular Research 2022 December;34(4):187-95

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Biotechnology and Biomolecular Research 2022 December;34(4):187-95

DOI: 10.23736/S2724-542X.22.02931-5

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Daturalactones as immunomodulators: activation of immune cells conferring cytotoxicity towards colon and pancreatic cancer cells

Gourav CHANDAN 1, Chetan KUMAR 2, Naresh K. SATTI 2, Hardeep S. TULI 3, Sharmila FAGOONEE 4, Shafiul HAQUE 5, Adesh K. SAINI 1, 3, Reena V. SAINI 1, 3

1 Central Research Cell, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, India; 2 Division of Natural Products Chemistry, Council of Scientific and Industrial Research-Indian Institute of Integrative Medicine, Jammu, India; 3 Department of Biotechnology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, India; 4 Institute of Biostructure and Bioimaging (CNR), Molecular Biotechnology Center, Turin, Italy; 5 Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia



Datura stramonium L. is an important Ayurvedic herb of the nightshade family (Solanaceae) used in the treatment of innumerable diseases for centuries. Previously, we reported the isolation of three steroidal lactones (Daturalactone (D1), 12-Deoxywithastramonalide (D23), and Daturilin (D27) from D. stramonium L. The present study was designed to evaluate in vitro immunomodulatory potential of these lactones on human peripheral blood mononuclear cells (PBMC). The data revealed that the lactones from D. stramonium significantly enhanced the proliferation of the human PBMC and increased the IL-2, IFN-γ, and TNF-α secretion. Flow cytometry data showed a significant up-regulation of CD3, CD8, and CD56 expression on PBMC. Enhanced intracellular granulysin expression was also observed in Datura lactones treated PBMC. Granulysin is an immunomarker and enhanced expression of granulysin depict activation of Cytotoxic T Lymphocytes and Natural Killer cells. Further, the micro-cytotoxicity assay was performed by co-culturing lactone-activated lymphocytes and target cells (colon cancer cells; HCT-116 and SW620, and pancreatic cancer cells; Panc-1 cells). The human PBMC activated with the lactones exhibited enhanced cancer cell death as compared to the untreated PBMC. It was found that the D27-treated lymphocytes showed higher cancer-killing potential as compared to D1- or D23-activated immune cells. Additionally, mechanistic studies showed that the stimulated lymphocytes enhanced ROS production and loss of mitochondrial membrane potential in the target cancer cells. The current study showed immuno-potentiating effects of D. stramonium lactones on human PBMC.


KEY WORDS: Datura stramonium; Leukocytes, mononuclear; Cytokines; Membrane potential, mitochondrial

top of page